comprehensive -WSS

comprehensive

author：explore 2025-10-02 00:51:51 - browse：3

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Pregnancy ages women, but effects reverse after delivery

WSS

Key Senate committee drafts bipartisan bill to stem drug shortages

Erich Jarvis studies song birds to learn about human stuttering

Why rehabilitation engineers need to center patients in their research

Diversity in clinical trials starts with building trust, experts say

Cue Health's Covid

Dogs on Prozac: What pet anti

entertainment

comprehensive

knowledge

Medicare details structure of new drug price negotiation program

6 surprising facts about sugar

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Close Medicare's dangerous gaps in addiction treatment coverage

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bring on the sabbaticals for nurses

New air purifier tech could be key to improving indoor air quality

Bring on the sabbaticals for nurses

United colonoscopy coverage change 'may cost lives,' doctors say

More tobacco lobbyists active in statehouses

focus

After traumatic brain injury, life support decisions can use more time

Cell therapy fails to slow type 1 diabetes, but safety is established

Biotech investment managers search for lucrative opportunities

Adam's Take: Intra

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Cancer, immunology, HIV research ensnared in fetal tissue politics

entertainment

leisure time

focus

explore